Chinese Medicine for Patients With Psoriasis

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 21, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness of a Chinese medicine formula called "Inflammatory Skin Disease Formula" (ISDF) for treating patients with psoriasis, a skin condition that causes red, scaly patches, often leading to discomfort and a reduced quality of life. The study aims to see if ISDF can help improve symptoms in patients with mild to moderate chronic plaque psoriasis. Participants will be randomly assigned to either receive the ISDF treatment or a placebo (a treatment that looks the same but has no active ingredients) for 12 weeks.

To be eligible for the trial, participants generally need to be adults aged between 18 and 65 years with mild to moderate psoriasis, as measured by a specific scoring system. However, individuals with more severe forms of psoriasis, those currently using certain medications, or who have specific health issues may not qualify. Throughout the trial, participants can expect regular check-ins and assessments to monitor their progress. This study is an opportunity for patients who may be seeking alternative treatment options, especially if they have found traditional treatments to be costly or have experienced side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Mild to moderate chronic plaque psoriasis (PASI score 3 to 12).
• • Willingness to give informed consent.
• Exclusion Criteria:
• • Pustular or generalized erythrodermic psoriasis.
• • Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory.
• • Systemic therapy for psoriasis 6 months prior to baseline.
• • Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus.
• • Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline.
• • UV light therapy 30 days prior to baseline.
• • Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range).
• • History of allergy to Chinese herbs.
• • Unwillingness to comply with study protocol.
• • Any other condition that in the opinion of the investigators could compromise the study.